

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number
WO 2004/009591 A1

(51) International Patent Classification⁷: **C07D 471/04**

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/IN2003/000207

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 2 June 2003 (02.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
545/MAS/2002 22 July 2002 (22.07.2002) IN

Declarations under Rule 4.17:



— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,

[Continued on next page]

(54) Title: A PROCESS FOR THE PREPARATION OF ANTISSCHIZOPHRENIC RISPERIDONE

WO 2004/009591 A1




(57) Abstract: This invention relates to a process for the preparation of antipsychotic risperidone (Formula I); which comprises reacting 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (Formula II); with 4-(2,4-difluorobenzoyl)piperidine oxime (Formula III); to form oxime (Formula IV); and *in situ* cyclization of oxime (Formula IV) to form risperidone (Formula I) in a solvent selected from the group consisting of acetonitrile, *N,N*-dimethylformamide and methyl isobutyl ketone.



- SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only
- Published:
- with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

TITLE**A PROCESS FOR THE PREPARATION OF ANTIPSYCHOTIC RISPERIDONE****PRIOR ART**


Risperidone (Compound I) is an antipsychotic agent belonging to 3-piperidinyl-1,2-benzisoxazole derivative reported by Janssen Pharmaceutica in US Patent 4,804,663.




Compound I

It has chemical name 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.


In US Patent 4,804,663, it is prepared by N-alkylation of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole (Compound V) with 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (Compound II) in dimethylformamide solvent using sodium carbonate base and potassium iodide catalyst in 46% yield. The product prepared in this manner often requires extensive purification.




The benzisoxazole intermediate (Compound V) required in this route of risperidone synthesis has been prepared in US Patent 4,804,663 and US Patent 5,134,147 by cyclization of 4-(2,4-difluorobenzoyl)piperidine oxime (Compound III) in aqueous sodium hydroxide solution.



In Spanish Patent ES 2 050 069, an alternate synthesis of risperidone is disclosed where 4-(2,4-difluorobenzoyl)piperidine hydrochloride (Compound VI) is reacted with 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (Compound II) in presence of sodium bicarbonate and potassium iodide to obtain 3-[2-[4-(2,4-difluorobenzoyl)piperidino]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one dihydrochloride (Compound VII) which is then reacted with hydroxyl amine hydrochloride in ethanol in presence of pyridine and potassium hydroxide to obtain the oxime compound (Compound IV). The isolation of oxime and its purification from ethyl acetate is reported before cyclization to obtain risperidone (Compound I).






This approach of preparing risperidone involves number of chemical steps and results in an overall yield of 40%.

The aim of the present invention is to provide a method to obtain highly pure risperidone in high yield.

DESCRIPTION OF THE INVENTION

The instant invention relates to an industrially advantageous, economic and efficient method for the preparation of highly pure risperidone.

The process comprises reacting 4-(2,4-difluorobenzoyl)piperidine oxime hydrochloride (Compound III) with 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monochloride (Compound II) in a solvent such as acetonitrile, methyl isobutyl ketone, *N,N*-Dimethylformamide using potassium carbonate or sodium carbonate base in presence of catalytic amount of potassium iodide to obtain an intermediate oxime (Compound IV) that cyclizes *in situ* to produce risperidone. The product thus produced is crystallized from ethyl acetate to obtain highly pure risperidone in 81% yield.



In the instant process, single pot reaction of Compound III with Compound II results in risperidone. This eliminates one chemical step of subjecting Compound III to preparation of isoxazole Compound V prior to reaction with Compound II (US Patent 4,804,663). Further, this route advantageously does not require the isolation and purification of intermediate, 3-[2-[4-[1-(2,4-difluorophenyl)-1-(hydroxyimino)methyl]piperidino]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-4-one (Compound IV), which means fewer number of process operations resulting in safety and cost effectiveness. Using the process according to the invention, risperidone is isolated from the reaction mixture directly in highly pure form and high yield.

The following specific examples illustrate the process of this invention.

Example-1

A mixture of 5.58 g of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride, 5.1 g of 4-(2,4-difluorobenzoyl)piperidine oxime hydrochloride, 0.46 g of potassium iodide, 6.76 g of anhydrous powdered potassium carbonate and 40 ml of acetonitrile was stirred and refluxed for 30 hours. Reaction monitoring by HPLC analysis indicated the formation of N-alkylated product, oxime, which subsequently slowly cyclized *in situ* to give risperidone. Thereafter, the reaction mixture was cooled and filtered. Residue was washed with cold water (50 ml) to remove the inorganics. Further washed with chilled ethyl acetate (5 ml). The product was crystallized from ethyl acetate yielding 6 g (81%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazole-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a] pyrimidin-4-one.

Example-2

A mixture of 4.75 g of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride, 5.1 g of 4-(2,4-difluorobenzoyl)piperidine oxime hydrochloride, 0.46 g of potassium iodide, 6.5 g of anhydrous powdered potassium carbonate and 30 ml of acetonitrile was stirred and refluxed for 30 hours. Reaction monitoring by HPLC analysis indicated *in situ* formation of risperidone. After the completion of reaction, the reaction mixture was cooled and water (120 ml) was added under stirring. Separated

solid stirred at 5°C for 1 hour, filtered, washed with water and crystallized from ethyl acetate yielding 6 g (81%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazole-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a] pyrimidin-4-one.

Example-3

A mixture of 4.75 g of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one hydrochloride, 5.1 g of 4-(2,4-difluorobenzoyl)piperidine oxime hydrochloride, 0.46 g of potassium iodide, 6.5 g of anhydrous powdered potassium carbonate and 30 ml of *N,N*-dimethylformamide was stirred at 95-100°C for 18 hours. The reaction mixture was cooled and water (120 ml) was added under stirring. Separated solid stirred at 5°C for 1 hour, filtered, washed with water and crystallized from ethyl acetate yielding 5.7 g (77%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazole-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.

Example-4

A mixture of 4.75 g of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one hydrochloride, 5.1 g of 4-(2,4-difluorobenzoyl)piperidine oxime hydrochloride, 0.46 g of potassium iodide, 6.5 g of anhydrous powdered potassium carbonate and 30 ml of MIBK was stirred at 100-105°C for 30 hours. The reaction mixture was cooled and water (150 ml) was added under stirring. Separated solid stirred at 5°C for 1 hour, filtered, washed with water and crystallized from ethyl acetate yielding 5.4 g (73%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazole-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.

Example-5


A mixture of 4.75 g of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 6.0 g of 4-(2,4-difluorobenzoyl)piperidine oxime hydrochloride, 0.46 g of potassium iodide, 6.1 g of anhydrous powdered potassium carbonate and 40 ml of acetonitrile was stirred and refluxed for 30 hours. The reaction mixture was cooled and water (120 ml) was added under stirring. Separated solid stirred at 5°C for 1 hour, filtered, washed with water. Crude product was purified by crystallization in ethyl acetate to afford 6.8 g (79%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazole-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a] pyrimidin-4-one.

Example-6

A mixture of 4.75 g of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride, 5.1 g of 4-(2,4-difluorobenzoyl)piperidine oxime hydrochloride, 0.46 g of potassium iodide, 5 g of anhydrous sodium carbonate and 30 ml of acetonitrile was stirred and refluxed for 32 hours. The reaction mixture was cooled and water (120 ml) was added under stirring. Separated solid stirred at 5° for 1 hour, filtered, washed with water and crystallized from ethyl acetate yielding 6 g (81%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazole-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a] pyrimidin-4-one.


CLAIMS:

(I) A method of preparing risperidone (Compound I)




Compound I

which comprises reacting 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (Compound II)




Compound II

with 4-(2,4-difluorobenzoyl)piperidine oxime (Compound III)



Compound III

to form oxime (Compound IV)



Compound IV

and *in situ* cyclization of oxime (Compound IV) to form risperidone (Compound I) in a solvent selected from the group consisting of acetonitrile, *N,N*-dimethylformamide and methyl isobutyl ketone.

- (2) A method according to Claim 1 wherein the reaction is carried out with a base such as anhydrous powdered potassium carbonate or sodium carbonate in presence of potassium iodide as catalyst.
- (3) A method according to Claim 1 wherein the reaction is carried out at a temperature in the range of 75°C to 110°C.
- (4) A method according to Claim 1 wherein risperidone produced is purified by crystallization from an organic solvent preferably ethyl acetate.
- (5) A method for preparing risperidone substantially as herein described with reference to the examples.

INTERNATIONAL SEARCH REPORT

| |
|---|
| International Application No PCT/IN 03/00207 |
|---|

| |
|---|
| A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D471/04 |
|---|

| |
|---|
| According to International Patent Classification (IPC) or to both national classification and IPC |
|---|

| |
|--------------------|
| B. FIELDS SEARCHED |
|--------------------|

| |
|---|
| Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D |
|---|

| |
|---|
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched |
|---|

| |
|--|
| Electronic data base consulted during the International search (name of data base and, where practical, search terms used) |
|--|

| |
|--|
| EPO-Internal, WPI Data, PAJ, CHEM ABS Data |
|--|

| |
|--|
| C. DOCUMENTS CONSIDERED TO BE RELEVANT |
|--|

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| P, X | WO 03 042212 A (CLEMENTIS GYOERGY ;EGYT GYOGYSZERVEGYESZETI GYAR (HU); KOERTVELYES) 22 May 2003 (2003-05-22) claim 1; examples --- | 1-5 |
| Y | WO 95 14691 A (JANSSEN PHARMACEUTICA NV ;VANDENBERK JAN (BE); KENNIS LUDO EDMOND) 1 June 1995 (1995-06-01) page 5 -page 6 --- | 1-5 |
| Y | ES 2 050 069 A (VITA INVEST SA) 1 May 1994 (1994-05-01) cited in the application column 2 -column 3 --- | 1-5 |
| Y | EP 0 453 042 A (JANSSEN PHARMACEUTICA NV) 23 October 1991 (1991-10-23) page 4 -page 5 --- | 1-5 |
| | -/- | |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

| | |
|---|--|
| Date of the actual completion of the International search | Date of mailing of the International search report |
|---|--|

| | |
|-------------------|------------|
| 22 September 2003 | 13/10/2003 |
|-------------------|------------|

| | |
|---|--------------------|
| Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016 | Authorized officer |
|---|--------------------|

| |
|--------------------|
| Authorized officer |
|--------------------|

| |
|----------|
| Fazzi, R |
|----------|

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN 03/00207

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | US 5 134 147 A (PEGLION JEAN L ET AL) 28 July 1992 (1992-07-28) cited in the application column 7 -column 8 ---- | 1-5 |
| A | US 4 804 663 A (KENNIS LUDO E J ET AL) 14 February 1989 (1989-02-14) cited in the application the whole document ---- | 1-5 |
| Y | "RISPERIDONE" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 13, no. 12, 1 December 1988 (1988-12-01), pages 1052-1055, XP002046839 ISSN: 0377-8282 page 1053 ----- | 1-5 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

 International Application No
 PCT/IN 03/00207

| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
|--|---|------------------|----|-------------------------|--|------------------|
| WO 03042212 | A | 22-05-2003 | WO | 03042212 A1 | | 22-05-2003 |
| WO 9514691 | A | 01-06-1995 | AT | 184281 T | | 15-09-1999 |
| | | | AU | 687940 B2 | | 05-03-1998 |
| | | | AU | 1065495 A | | 13-06-1995 |
| | | | CA | 2175372 A1 | | 01-06-1995 |
| | | | DE | 69420579 D1 | | 14-10-1999 |
| | | | DE | 69420579 T2 | | 27-04-2000 |
| | | | DK | 730594 T3 | | 27-03-2000 |
| | | | WO | 9514691 A1 | | 01-06-1995 |
| | | | EP | 0730594 A1 | | 11-09-1996 |
| | | | ES | 2137486 T3 | | 16-12-1999 |
| | | | FI | 962155 A | | 22-05-1996 |
| | | | GR | 3031500 T3 | | 31-01-2000 |
| | | | JP | 9505574 T | | 03-06-1997 |
| | | | RU | 2126406 C1 | | 20-02-1999 |
| | | | SI | 730594 T1 | | 31-12-1999 |
| | | | US | 5688799 A | | 18-11-1997 |
| ES 2050069 | A | 01-05-1994 | ES | 2050069 A1 | | 01-05-1994 |
| EP 0453042 | A | 23-10-1991 | AT | 186301 T | | 15-11-1999 |
| | | | AU | 636969 B2 | | 13-05-1993 |
| | | | AU | 7436691 A | | 24-10-1991 |
| | | | BG | 60394 B1 | | 28-02-1995 |
| | | | CA | 2040086 A1 | | 20-10-1991 |
| | | | CN | 1055929 A ,B | | 06-11-1991 |
| | | | CS | 9101099 A2 | | 12-11-1991 |
| | | | DE | 69131759 D1 | | 09-12-1999 |
| | | | DE | 69131759 T2 | | 21-06-2000 |
| | | | DK | 453042 T3 | | 25-04-2000 |
| | | | EP | 0453042 A1 | | 23-10-1991 |
| | | | ES | 2140381 T3 | | 01-03-2000 |
| | | | FI | 911885 A ,B, | | 20-10-1991 |
| | | | GR | 3032122 T3 | | 27-04-2000 |
| | | | HU | 57763 A2 | | 30-12-1991 |
| | | | IE | 911301 A1 | | 23-10-1991 |
| | | | IL | 97892 A | | 30-03-1995 |
| | | | JP | 3216889 B2 | | 09-10-2001 |
| | | | JP | 4234882 A | | 24-08-1992 |
| | | | KR | 190297 B1 | | 01-06-1999 |
| | | | NO | 911525 A ,B, | | 21-10-1991 |
| | | | NZ | 237713 A | | 25-09-1992 |
| | | | PL | 289935 A1 | | 06-04-1992 |
| | | | PL | 169744 B1 | | 30-08-1996 |
| | | | PT | 97395 A ,B | | 31-01-1992 |
| | | | SK | 279005 B6 | | 06-05-1998 |
| | | | RU | 2037495 C1 | | 19-06-1995 |
| | | | US | 5482943 A | | 09-01-1996 |
| | | | ZA | 9102913 A | | 30-12-1992 |
| US 5134147 | A | 28-07-1992 | FR | 2654104 A1 | | 10-05-1991 |
| | | | AT | 110075 T | | 15-09-1994 |
| | | | AU | 631466 B2 | | 26-11-1992 |
| | | | AU | 6581990 A | | 16-05-1991 |
| | | | CA | 2029372 A1 | | 08-05-1991 |
| | | | DE | 69011628 D1 | | 22-09-1994 |
| | | | DK | 428437 T3 | | 02-01-1995 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IN 03/00207

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|---|--|
| US 5134147 | A | EP 0428437 A1 ES 2062458 T3 IE 903992 A1 JP 1959184 C JP 3188077 A JP 6092403 B NZ 235892 A OA 9468 A PT 95808 A ,B US 5100902 A ZA 9008884 A | 22-05-1991 16-12-1994 08-05-1991 10-08-1995 16-08-1991 16-11-1994 26-08-1992 15-11-1992 13-09-1991 31-03-1992 28-08-1991 |
| US 4804663 | A 14-02-1989 | SG 119294 G CS 9103822 A3 SK 280125 B6 AU 579232 B2 AU 5529786 A BG 60432 B2 CA 1256867 A1 CN 86101906 A ,B CY 1801 A DK 143986 A EP 0196132 A2 HK 108794 A IE 58388 B1 JP 1908510 C JP 6013511 B JP 61221186 A LU 88576 A9 SU 1468419 A3 AT 79379 T DE 3686341 D1 DE 3686341 T2 ES 8705881 A1 FI 861328 A ,B, FI 893001 A GR 860800 A1 HU 42461 A2 IL 78250 A KR 9100165 B1 KR 9100437 B1 LT 2071 R3 LV 5043 A3 LV 5778 A4 NO 861230 A ,B, NZ 215462 A PH 24016 A PT 82254 A ,B ZA 8602279 A | 17-03-1995 13-05-1992 06-08-1999 17-11-1988 02-10-1986 31-03-1995 04-07-1989 01-10-1986 17-02-1995 28-09-1986 01-10-1986 14-10-1994 08-09-1993 24-02-1995 23-02-1994 01-10-1986 21-03-1995 23-03-1989 15-08-1992 17-09-1992 14-01-1993 01-08-1987 28-09-1986 19-06-1989 21-07-1986 28-07-1987 12-05-1991 21-01-1991 25-01-1991 15-06-1993 10-06-1993 20-12-1996 29-09-1986 29-09-1988 09-02-1990 01-04-1986 25-11-1987 |